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A B S T R A C T
Invasive aspergillosis due to azole-resistant Aspergillus fumigatus is diﬃcult to manage. We describe a case of
azole-resistant invasive aspergillosis in a female bottlenose dolphin, who failed to respond to voriconazole and
posaconazole therapy. As intravenous therapy was precluded, high dose posaconazole was initiated aimed at
achieving trough levels exceeding 3 mg/l. Posaconazole serum levels of 3–9.5 mg/l were achieved without
signiﬁcant side-eﬀects. Follow-up bronchoscopy and computed tomography showed complete resolution of the
lesions.
1. Introduction
Azoles remain the corner-stone of prevention and treatment of
aspergillus diseases, including acute invasive aspergillosis (IA) [1].
However, the clinical use of azoles is threatened by the emergence of
azole resistance in Aspergillus fumigatus, the primary cause of IA in many
regions of the world [2]. Resistance that arises through the environ-
mental use of azole fungicides is believed to be an important driver of
azole-resistant cases [3]. This route of resistance development proves a
clinical challenge with cases of azole-resistant IA occurring in patients
without previous azole therapy [4,5], and cases of azole-susceptible and
azole-resistant A. fumigatus co-infection [6]. Resistance mutations
commonly confer resistance to multiple azole drugs, including the
recently clinically-licensed isavuconazole [7]. However, based on in
vitro and experimental models it was hypothesized that low-level azole-
resistant A. fumigatus infection might be successfully treated with
voriconazole or posaconazole provided that the treatment dose and
exposure could be increased [8].
We describe a case of azole-resistant IA in a bottlenose dolphin that
was successfully managed by increasing posaconazole exposure.
2. Case
A 10 year old female captive bottlenose dolphin (Tursiops truncatus),
weighing 175 kg, was treated with antibiotics for bacterial pneumonia
caused by Vibrio alginolyticus. Treatment follow-up was conducted with
blood samples, CT-scans, bronchoscopies, and protected brush samples
from the tracheal and/or bronchial mucosa for histopathology and
bacterial and fungal culture (Fig. 1).
The bacterial pneumonia required long-term antibiotic treatment
and 6 months into therapy she developed multiple white, raised lesions
in the trachea and bronchi, one of which was sampled with protected
brush during bronchoscopy. No fungi were cultured but based on the
bronchoscopic appearance of the lesions a Candida infection was
suspected. Treatment with oral voriconazole with a loading dose of
5.5 mg/kg per day during 3 days and a maintenance dose of 5.5 mg/kg
per week (given in one single dose) was started. Follow-up bronchos-
copies were performed one, two and three months after voriconazole
treatment was started, showing no improvement. Fungal culture of a
protected brush sample, taken at one and two months of voriconazole
therapy remained negative, but at three months A. fumigatus was
cultured. Retrospective analysis of a serum sample indicated the
presence of circulating galactomannan (GM; GM-index 6.5). The A.
fumigatus isolate was sent to the Mycology Reference Laboratory and
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was found to be resistant to voriconazole with a MIC of> 16 mg/l and
a posaconazole MIC of 0.5 mg/l. The strain harbored the TR46/Y121F/
T289A resistance mutation in the cyp51A-gene. Treatment was then
changed to posaconazole at a dose of 600 mg/day (day 0). The oral
solution formulation of posaconazole was used, which was incorporated
in gelatin capsules and placed into the ﬁsh she was fed. The daily dose
was divided into two doses and administered in the morning and late
afternoon. Posaconazole therapeutic drug monitoring was performed
aiming at a target trough level of> 1 mg/l. The clinical condition of the
dolphin initially improved and follow-up bronchoscopy on days 29,
101, and 232 showed stable disease. Monitoring of posaconazole
plasma levels conﬁrmed levels of> 1 mg/l. However, the clinical
condition of the dolphin deteriorated and a new bronchoscopy on day
279 showed increased lesion size. The posaconazole dose was increased
on day 286 to achieve plasma levels above 2 mg/l. However, this did
not result in clinical improvement nor reduction of the size of the
trachea lesions.
After 344 days of posaconazole therapy, a higher exposure target
was advised based on preclinical studies, aiming at a plasma level
of> 3 mg/l [8]. This drug level was ﬁrst achieved on day 356 of
posaconazole therapy. After initial clinical deterioration and stable size
of the lesions, the dolphin started to improve clinically, which was
supported by resolution of the lesions on the CT-scan (Fig. 2). The
improvement further was conﬁrmed with bronchoscopy showing
complete resolution of the lesions on day 459. Posaconazole plasma
levels varied between 3 and 9.5 mg/l, with doses ranging from 800 to
1800 mg/day (Fig. 3). After a total treatment duration of 593 days
posaconazole therapy was discontinued.
The A. fumigatus isolate recovered from the dolphin was identiﬁed
using beta-tubulin sequencing. MIC-testing using the EUCAST micro-
dilution reference method showed a MIC of 1 mg/l for amphotericin B,
high level-resistance (MIC> 16 mg/l) for itraconazole and voricona-
zole, and low-level resistance for posaconazole, 0.5 mg/l. A TR46/
Y121F/T289A resistance mutation was identiﬁed.
3. Discussion
We describe a case of pulmonary IA due to A. fumigatus in a
bottlenose dolphin that was complicated by azole resistance. The
fungus was cultured from plaques in the trachea and bronchi that were
visualized through bronchoscopy, and computed tomography showed
pulmonary lesions consistent with fungal disease. Furthermore, circu-
lating GM was detected in the serum at diagnosis. Although GM
detection is a well validated diagnostic tool in humans for the diagnosis
of invasive aspergillosis and for treatment response evaluation [9,10],
the performance of the assay in dolphins remains unclear. As IA is the
most commonly reported in fungal disease in captive and free-ranging
bottlenose dolphins, [11–13] further studies are needed to determine
the performance of this biomarker in dolphins and other cetaceans. In
addition to bronchoscopy, the presence of circulating GM would help to
diagnose Aspergillus infection and possibly be useful for monitoring of
treatment response. GM however does not identify the species of
Aspergillus that is causing the fungal pneumonia, nor does it provide
information regarding the presence of resistance. Additional tests
would be required either through culture or molecular tests of
respiratory specimens. PCR-tests that identify the most prevalent
Aspergillus species as well as the presence of azole resistance mutations
are commercially available [14]. In humans such assays enabled the
detection of azole-resistant A. fumigatus directly in BAL-ﬂuid [14,15].
The A. fumigatus strain recovered from our case harbored a resistance
mutation that is associated with environmental resistance selection [5],
indicating that the dolphin inhaled A. fumigatus conidia that were
already azole-resistant.
Treatment options in humans and animals with azole-resistant IA
are limited. Experts recommended to move away from azole mono-
therapy when resistance is documented, switching to liposomal am-
photericin B or voriconazole and echinocandin combination therapy
[16]. In vitro and in vivo studies indicate that the activity of polyenes
and echinocandins are not aﬀected by the presence of azole resistance
mutations [17–19]. Furthermore, voriconazole and anidulafungin com-
bination therapy was shown to be eﬀective in an animal model of
disseminated IA due to A. fumigatus with low-level voriconazole
resistance (MIC of 4 mg/l). However, the eﬃcacy of the combination
against voriconazole high-level resistant A. fumigatus has not been
studied [18]. There is concern that voriconazole will not be eﬀective in
high-level resistant A. fumigatus infection and combination therapy will
solely rely on anidulafungin eﬃcacy, which is suboptimal [18].
As intravenous therapy was no option in treating the dolphin, it was
decided to increase the exposure of posaconazole. Using results of
pharmacokinetic and pharmacodynamic in vitro and in vivo models we
have previously attempted to bridge these experimental results to
human infection by calculating which posaconazole exposure would
be required in relation to the A. fumigatus MIC to treat successfully [8].
For each MIC the corresponding posaconazole exposure and plasma
level were determined [8]. Based on our analysis a posaconazole
plasma-level of 3.09–3.33 mg/l would be required to treat an infection
with a posaconazole MIC of 0.5 mg/l and 6.18–6.66 mg/l for a MIC of
1.0 mg/l [8]. Indeed when a plasma level of> 3 mg/l was achieved in
the dolphin, gradual clinical response was documented without sig-
niﬁcant toxicity ultimately leading to clinical cure.
In the dolphin very high drug exposures were achieved using the
oral solution formulation, but in humans posaconazole drug levels
above 3 mg/l could not be achieved due to limited bioavailability
associated with the oral suspension. However, phase I and phase II
pharmacokinetic studies indicate that a posaconazole plasma level
above 3 mg/l can be achieved using the new intravenous and tablet
formulations, without signiﬁcant side-eﬀects [20]. As the majority of
azole-resistant A. fumigatus isolates show low-level resistance to
posaconazole, i.e. within the 0.5 mg/l to 1 mg/l MIC range [17],
intravenous posaconazole might be a treatment option in human cases
of azole-resistant IA.
Our study shows proof-of-principle of high-dose posaconazole for
the treatment of IA due to posaconazole low-level-resistant A. fumigatus.
With the availability of new posaconazole formulations further studies
need to explore this option for the management of azole-resistant IA in
animals and humans.
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Fig. 1. Overview of bronchoscopy's and computed tomography's (CT) performed as part
of the management of the respiratory infections in the bottlenose dolphin and the
antimicrobial treatments. AB, antibacterial therapy; VCZ, voriconazole; POS, posacona-
zole. Day 0 represents the ﬁrst day of posaconazole therapy.
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Fig. 2. Evolution of pulmonary lesions on consecutive CT-scans of the lung at the level of the heart. Panel A, Axial CT image, taken before high-dose posaconazole treatment was started,
showing small granulomas and some inﬁltrates at the left side; Panel B, At 6 weeks of high dose posaconazole therapy. The CT image shows a progression of the granulomas at the left side
and some inﬁltrates at both sides; Panel C, After 14 weeks of posaconazole high-dose therapy, showing a substantial reduction of the granulomas and inﬁltrates; Panel D, CT imaging after
22 weeks of high-dose posaconazole treatment showing complete resolution of the granulomas. Some residual peribronchial lesions are visible.
Fig. 3. Posaconazole dose (lower panel), posaconazole trough plasma levels (mg/l; middle panel) and consecutive bronchoscopy images of Aspergillus trachea lesions (upper panel). Green
indicates the area of posaconazole exposure calculated to be suﬃcient to successfully treat posaconazole low-resistant A. fumigatus (MIC 0.5 mg/l), while the red area represents
insuﬃcient posaconazole exposure. Day 0 indicates the ﬁrst day of posaconazole therapy. Posaconazole treatment was interrupted for 11 days (day 445–455) because the dolphin was
clinically poor and a possible side eﬀect of high-dose posaconazole needed to be ruled-out. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the
web version of this article).
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